S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
The Largest Ever Technology Wave Is Coming! (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
South African president appoints judge to oversee weapons-for-Russia inquiry
The Largest Ever Technology Wave Is Coming! (Ad)
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
The Largest Ever Technology Wave Is Coming! (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
South African president appoints judge to oversee weapons-for-Russia inquiry
The Largest Ever Technology Wave Is Coming! (Ad)
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
The Largest Ever Technology Wave Is Coming! (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
South African president appoints judge to oversee weapons-for-Russia inquiry
The Largest Ever Technology Wave Is Coming! (Ad)
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
The Largest Ever Technology Wave Is Coming! (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
South African president appoints judge to oversee weapons-for-Russia inquiry
The Largest Ever Technology Wave Is Coming! (Ad)
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
NASDAQ:CRVS

Corvus Pharmaceuticals (CRVS) News Today

$2.60
-0.20 (-7.14%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$2.57
$2.87
50-Day Range
$0.65
$3.37
52-Week Range
$0.61
$3.70
Volume
785,100 shs
Average Volume
514,193 shs
Market Capitalization
$121.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.17
Get Corvus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.



CRVS Media Mentions By Week

CRVS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CRVS
News Sentiment

0.30

0.78

Average
Medical
News Sentiment

CRVS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CRVS Articles
This Week

3

1

CRVS Articles
Average Week

SourceHeadline
finance.yahoo.com logoIs Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
finance.yahoo.com - May 26 at 1:52 PM
MarketBeat logoCorvus Pharmaceuticals (NASDAQ:CRVS) Research Coverage Started at StockNews.com
americanbankingnews.com - May 21 at 7:57 AM
MarketBeat logoCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Director Buys $24,500.00 in Stock
americanbankingnews.com - May 18 at 8:14 AM
finance.yahoo.com logoCorvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma
finance.yahoo.com - May 17 at 9:19 AM
seekingalpha.com logoCorvus Pharmaceuticals: Targeting $1 Billion/Year U.S. T-Cell Lymphoma Market
seekingalpha.com - May 12 at 6:35 PM
finance.yahoo.com logoCorvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Why
finance.yahoo.com - May 12 at 1:35 PM
finanznachrichten.de logoCorvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
finanznachrichten.de - May 10 at 8:04 PM
benzinga.com logoWhy Are Corvus Pharmaceuticals Trading Higher Today
benzinga.com - May 10 at 3:02 PM
msn.com logoCantor Fitzgerald Maintains Corvus Pharmaceuticals (CRVS) Overweight Recommendation
msn.com - May 9 at 7:23 PM
MarketBeat logoCorvus Pharmaceuticals (NASDAQ:CRVS) Price Target Raised to $4.00 at Cantor Fitzgerald
americanbankingnews.com - May 9 at 7:52 AM
MarketBeat logoCorvus Pharmaceuticals (NASDAQ:CRVS) Receives New Coverage from Analysts at StockNews.com
americanbankingnews.com - May 9 at 4:36 AM
MarketBeat logoCorvus Pharmaceuticals (CRVS) Set to Announce Earnings on Monday
americanbankingnews.com - May 7 at 3:48 AM
MarketBeat logoCorvus Pharmaceuticals (NASDAQ:CRVS) Now Covered by StockNews.com
americanbankingnews.com - April 29 at 4:26 AM
MarketBeat logoCorvus Pharmaceuticals (NASDAQ:CRVS) Coverage Initiated at StockNews.com
americanbankingnews.com - April 21 at 5:22 AM
finance.yahoo.com logoCorvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023
finance.yahoo.com - April 20 at 1:43 PM
finance.yahoo.com logoCorvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - April 17 at 9:28 AM
MarketBeat logoStockNews.com Initiates Coverage on Corvus Pharmaceuticals (NASDAQ:CRVS)
americanbankingnews.com - April 13 at 2:46 AM
MarketBeat logoCantor Fitzgerald Brokers Boost Earnings Estimates for Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)
americanbankingnews.com - April 5 at 2:50 AM
bizjournals.com logoCorvus Pharmaceuticals cut its CEO's base salary by $265,000. Here's the catch.
bizjournals.com - April 4 at 10:13 PM
MarketBeat logoCorvus Pharmaceuticals (NASDAQ:CRVS) Coverage Initiated by Analysts at StockNews.com
americanbankingnews.com - April 4 at 4:28 AM
finance.yahoo.com logoCPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma
finance.yahoo.com - April 3 at 10:26 AM
MarketBeat logoCorvus Pharmaceuticals (NASDAQ:CRVS) Receives Neutral Rating from Mizuho
americanbankingnews.com - April 3 at 3:52 AM
finance.yahoo.com logoCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2022 Earnings Call Transcript
finance.yahoo.com - March 30 at 8:54 AM
finanznachrichten.de logoCorvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
finanznachrichten.de - March 29 at 5:35 PM
finance.yahoo.com logoCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
finance.yahoo.com - March 28 at 4:21 PM
msn.com logoCorvus Pharmaceuticals Earnings Preview
msn.com - March 27 at 1:01 PM
MarketBeat logoCorvus Pharmaceuticals (NASDAQ:CRVS) Now Covered by Analysts at StockNews.com
americanbankingnews.com - March 27 at 4:30 AM
finance.yahoo.com logoCorvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023
finance.yahoo.com - March 21 at 7:51 PM
finance.yahoo.com logoCorvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - March 14 at 6:00 PM
finance.yahoo.com logoCorvus Pharma's HIV Candidate Shows Potential To Prevent Virus Re-Emergence
finance.yahoo.com - February 21 at 3:39 PM
finance.yahoo.com logoCorvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal
finance.yahoo.com - February 21 at 10:38 AM
finance.yahoo.com logo'Block-and-lock' HIV path targeted by UCSF professor, Peninsula drug company
finance.yahoo.com - February 21 at 10:38 AM
finance.yahoo.com logoQuite a few insiders invested in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) last year which is positive news for shareholders
finance.yahoo.com - February 2 at 9:25 AM
forbes.com logoCorvus Pharmaceuticals
forbes.com - January 20 at 10:37 PM
reuters.com logoCRVS.A - | Stock Price & Latest News | Reuters
reuters.com - January 13 at 1:56 PM
finance.yahoo.com logoCorvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition
finance.yahoo.com - December 12 at 3:34 PM
finance.yahoo.com logoCorvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022
finance.yahoo.com - December 5 at 6:06 PM
finance.yahoo.com logoJames Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatology
finance.yahoo.com - November 14 at 10:47 AM
apnews.com logoCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results
apnews.com - November 4 at 10:03 AM
finanznachrichten.de logoCorvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results
finanznachrichten.de - November 4 at 5:01 AM
finance.yahoo.com logoCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results
finance.yahoo.com - November 4 at 5:01 AM
finance.yahoo.com logoCorvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition
finance.yahoo.com - November 3 at 11:58 AM
msn.com logoEarnings Preview For Corvus Pharmaceuticals
msn.com - November 2 at 3:54 PM
finance.yahoo.com logoCorvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022
finance.yahoo.com - October 27 at 5:42 PM
finance.yahoo.com logoCorvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer
finance.yahoo.com - October 25 at 6:27 PM
finance.yahoo.com logoCorvus Pharma's Partner Secures China Approval For Early-Stage Mupadolimab Trial For Lung, Head & Neck Cancer
finance.yahoo.com - September 27 at 2:16 PM
finance.yahoo.com logoCorvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China
finance.yahoo.com - September 26 at 6:04 PM
nasdaq.com logoA number of insiders bought Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) stock last year, which is great news for shareholders
nasdaq.com - September 15 at 7:41 AM
finance.yahoo.com logoCorvus Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
finance.yahoo.com - September 6 at 5:50 PM
finance.yahoo.com logoGreat news for Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS): Insiders acquired stock in large numbers last year
finance.yahoo.com - August 26 at 7:06 AM
Get Corvus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:CRVS) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -